SAN FRANCISCO, Nov. 6 – Nanogen completed internal validation of a DNA-based research protocol for the MTHFR mutation to use on the NanoChip Molecular Biology Workstation, the company announced Tuesday.
MTHFR is associated with cardiovascular disease and the pathology of thrombosis. Protocol users will have the option to further develop and validate the protocols for internal use, the company said.
This is the fourth DNA-based research protocol that the San Diego-based company has internally validated for use on the NanoChip Molecular Biology Workstation.